Eagle Pharmaceuticals, Inc.
50 Tice Boulevard, Suite 315
Woodcliff Lake, New Jersey 07677
October 17, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Alan Campbell | |
Re: | Eagle Pharmaceuticals, Inc. | |
Registration Statement on Form S-3 (File No. 333-267827) | ||
Request for Acceleration of Effective Date |
Mr. Campbell:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-267827) (the “Registration Statement”) to become effective on October 19, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Sarah Sellers of Cooley LLP, counsel to the Registrant, at (212) 479-6370, or in her absence, Marc Recht at (617) 937-2316.
[Signature page follows]
Very truly yours, | ||
Eagle Pharmaceuticals, Inc. | ||
By: | /s/ Brian Cahill | |
Brian Cahill | ||
Chief Financial Officer |
cc: | |
Ryan Debski, Eagle Pharmaceuticals, Inc. | |
Brian Cahill, Eagle Pharmaceuticals, Inc. | |
Marc Recht, Cooley LLP | |
Sarah Sellers, Cooley LLP |
Signature Page to Company Acceleration Request – S-3